Cancer Cure: Israeli Scientists Develop 100% Effective Treatment For Cancer

The newly developed cancer cure treatment is called MuTaTo or Multitarget Toxin

In a major breakthrough, an Israeli group of scientists has found a 100% effective cure for cancer, which they claim will help to save millions of people around the world every year. Developed by Accelerated Evolution Biotechnologies Ltd. (AEBi), the newly developed cancer cure treatment is called MuTaTo or Multitarget Toxin.

The scientists reportedly carried out preliminary research and testing on mice using peptides made out of a chain of amino acids that only targets and terminates cancer cells, leaving alone healthy cells and tissue in the process. Satisfied with test results performed on mice, the scientists are now hoping to begin human clinical trials soon.

According to Dr. Morad, CEO of AEBi, MuTaTo will work where other cancer treatments fail. The prevailing cancer treatments don’t work effectively as the cancer cells it attacks mutate and spread to avoid the drug, thus rendering the treatment useless.

But in the case of MuTaTo, it attacks a cancer cell’s receptors from three different directions and doesn’t allow the cells to spread. Dr. Morad claims that MuTaTo destroys stem cells and penetrate where other drugs cannot reach. The newly developed cancer cure treatment dramatically decreases side effects because it does not target non-cancerous cells as current cancer drugs do.

“Instead of attacking receptors one at a time, we attack receptors three at a time,” Dr. Morad told The Jerusalem Post. “Not even cancer can mutate three receptors at the same time.”

He also ensured that the cancer treatment will be available at a much lower cost as compared to other treatments available in the market.

The biotech company is planning to try the medicines on humans through this year and hopefully introduce the medicine in the market by next year.

Caroline Finnegan

A professionnal journalist for the past ten years, I cover global news and economic affairs for The Chief Observer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *